Johnson & Johnson reports data from Phase II plaque psoriasis trial

Johnson & Johnson has reported results from the Phase II FRONTIER 1 clinical trial of JNJ-2113, an investigational oral peptide inhibitor targeting the IL-23 receptor, for plaque psoriasis (PsO).

The multicentre, double-blind, randomised, placebo-controlled trial is designed to analyse the safety and efficacy of JNJ-2113.